Causes of mortality from COVID-19 include respiratory failure, heart failure, and sepsis/multiorgan failure. TLR4 is an innate immune receptor on the cell surface that recognizes pathogen-associated molecular patterns (PAMPs) including viral proteins and triggers the production of type I interferons and proinflammatory cytokines to combat infection. It is expressed on both immune cells and tissue-resident cells. ACE2, the reported entry receptor for SARS-CoV-2, is only present on ~1-2% of the cells in the lungs or has a low pulmonary expression, and recently, the spike protein has been proposed to have the strongest protein-protein interaction with TLR4. Here, we review and connect evidence for SARS-CoV-1 and SARS-CoV-2 having direct and indirect binding to TLR4, together with other viral precedents, which when combined shed light on the COVID-19 pathophysiological puzzle. We propose a model in which the SARS-CoV-2 spike glycoprotein binds TLR4 and activates TLR4 signalling to increase cell surface expression of ACE2 facilitating entry. SARS-CoV-2 also destroys the type II alveolar cells that secrete pulmonary surfactants, which normally decrease the air/tissue surface tension and block TLR4 in the lungs thus promoting ARDS and inflammation. Furthermore, SARS-CoV-2-induced myocarditis and multiple-organ injury may be due to TLR4 activation, aberrant TLR4 signalling, and hyperinflammation in COVID-19 patients. Therefore, TLR4 contributes significantly to the pathogenesis of SARS-CoV-2, and its overactivation causes a prolonged or excessive innate immune response. TLR4 appears to be a promising therapeutic target in COVID-19, and since TLR4 antagonists have been previously trialled in sepsis and in other antiviral contexts, we propose the clinical trial testing of TLR4 antagonists in the treatment of severe COVID-19. Also, ongoing clinical trials of pulmonary surfactants in COVID-19 hold promise since they also block TLR4.
【초록키워드】 COVID-19, Treatment, SARS-CoV-2, Inflammation, ACE2, ARDS, clinical trial, Cytokines, Pathogenesis, Respiratory failure, Mortality, innate immune response, severe COVID-19, Antiviral, TLR4, spike glycoprotein, Infection, interferons, lung, Sepsis, Viral proteins, SARS-CoV-1, type I interferon, Spike protein, heart failure, Viral, pathogen, cells, myocarditis, SARS-CoV-2 spike glycoprotein, hyperinflammation, Lungs, immune cells, type I interferons, pathogen-associated molecular patterns, receptor, proinflammatory cytokines, expression, protein-protein interaction, COVID-19 patients, binding, Evidence, innate immune, Immune cell, PAMPs, Injury, Trigger, therapeutic target, Pulmonary surfactants, triggers, the strongest, the cell, surface tension, Proinflammatory cytokine, Activation, pathogen-associated molecular pattern, Viral protein, cell surface, causes, multiorgan failure, promise, entry receptor, pathogenesis of SARS-CoV-2, antagonist, tension, Cell, decrease, bind, significantly, include, reported, appear, contribute, recognize, the spike protein, expressed, alveolar cell, cause, activate, multiple-organ, pathophysiological, secrete, the SARS-CoV-2, 【제목키워드】 COVID-19, SARS-CoV-2, ACE2, causing, bind, increase, Facilitating,